Literature DB >> 15328114

Increased serum resistance in Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases.

H Sahly1, H Aucken, V J Benedí, C Forestier, V Fussing, D S Hansen, I Ofek, R Podschun, D Sirot, J M Tomás, D Sandvang, U Ullmann.   

Abstract

The aim of this study was to determine whether there is an association between serum resistance, O serotypes, and the production of extended-spectrum beta-lactamases (ESBLs) in Klebsiella pneumoniae. Ninety ESBL-producing and 178 non-ESBL-producing K. pneumoniae isolates gathered in five European countries were O serotyped and tested for sensitivity to the serum's bactericidal effect. The frequency of serum-resistant isolates was higher among ESBL-producing strains (30%; 27/90 isolates) than among non-ESBL-producing strains (17.9%; 32/178 isolates) (P = 0.037; odds ratio [OR] = 1.96; 95% confidence interval [95% CI] = 1.08 to 3.53). Although O1 was the most common O serotype in both Klebsiella groups, its frequency among ESBL-producing strains was significantly higher (59%; 53/90 isolates) than among non-ESBL producers (36%; 64/178 isolates) (P = 0.0006; OR = 2.5; 95% CI = 1.52 to 4.29). Furthermore, the prevalence of the O1 serotype was higher among serum-resistant strains of both ESBL-producing (74%; 20/27isolates) and non-ESBL producers (75%; 24/32 isolates) than among serum-sensitive ESBL producers (52.4%; 33/63 isolates) and non-ESBL producers (27.4%; 40/146 isolates). Serum resistance among ESBL-producing strains (36%; 17/47 isolates) versus non-ESBL-producing strains (16%; 27/166 isolates) was also significantly higher after the exclusion of clonal strains (P = 0.0056; OR = 2.9; 95% CI = 1.41 to 6.01). Sixteen ESBL types were detected, among which the frequency of serum resistance was significantly lower among the SHV-producing strains (9/48 isolates) than among the TEM producers (16/35 isolates) (P = 0.016; OR = 3.65; CI = 1.3 to 9.7). Curing ESBL-coding plasmids did not influence the serum resistance of the bacteria; all six plasmid-cured derivatives maintained serum resistance. The present findings suggest that ESBL-producing strains have a greater pathogenic potential than non-ESBL-producing strains, but the linkage between O serotypes, serum resistance, and ESBL production remains unclear at this stage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328114      PMCID: PMC514775          DOI: 10.1128/AAC.48.9.3477-3482.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing.

Authors:  S Merino; S Camprubí; S Albertí; V J Benedí; J M Tomás
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

Review 2.  Antimicrobial-resistant pathogens in the 1990s.

Authors:  G A Jacoby
Journal:  Annu Rev Med       Date:  1996       Impact factor: 13.739

3.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

4.  C1q binding and activation of the complement classical pathway by Klebsiella pneumoniae outer membrane proteins.

Authors:  S Albertí; G Marqués; S Camprubí; S Merino; J M Tomás; F Vivanco; V J Benedí
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

5.  Somatic serogroups, capsular types, and species of fecal Klebsiella in patients with ankylosing spondylitis.

Authors:  P Toivanen; D S Hansen; F Mestre; L Lehtonen; J Vaahtovuo; M Vehma; T Möttönen; R Saario; R Luukkainen; M Nissilä
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

6.  A new fimbrial antigen harbored by CAZ-5/SHV-4-producing Klebsiella pneumoniae strains involved in nosocomial infections.

Authors:  P Di Martino; V Livrelli; D Sirot; B Joly; A Darfeuille-Michaud
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

7.  Selective pressures and lipopolysaccharide subunits as determinants of resistance of clinical isolates of gram-negative bacilli to human serum.

Authors:  R Porat; M A Johns; W R McCabe
Journal:  Infect Immun       Date:  1987-02       Impact factor: 3.441

8.  R-plasmid-encoded adhesive factor in Klebsiella pneumoniae strains responsible for human nosocomial infections.

Authors:  A Darfeuille-Michaud; C Jallat; D Aubel; D Sirot; C Rich; J Sirot; B Joly
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

9.  Serotypes, hemagglutinins, siderophore synthesis, and serum resistance of Klebsiella isolates causing human urinary tract infections.

Authors:  R Podschun; D Sievers; A Fischer; U Ullmann
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

10.  Structural variation in the O-specific polysaccharides of Klebsiella pneumoniae serotype O1 and O8 lipopolysaccharide: evidence for clonal diversity in rfb genes.

Authors:  R F Kelly; W B Severn; J C Richards; M B Perry; L L MacLean; J M Tomás; S Merino; C Whitfield
Journal:  Mol Microbiol       Date:  1993-11       Impact factor: 3.501

View more
  26 in total

1.  Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.

Authors:  Mario Tumbarello; Teresa Spanu; Maurizio Sanguinetti; Rita Citton; Eva Montuori; Fiammetta Leone; Giovanni Fadda; Roberto Cauda
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Recognition of bacterial surface polysaccharides by lectins of the innate immune system and its contribution to defense against infection: the case of pulmonary pathogens.

Authors:  Hany Sahly; Yona Keisari; Erika Crouch; Nathan Sharon; Itzhak Ofek
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

3.  Occurrence of the CTX-M, SHV and the TEM Genes Among the Extended Spectrum β-Lactamase Producing Isolates of Enterobacteriaceae in a Tertiary Care Hospital of North India.

Authors:  Maninder Kaur; Aruna Aggarwal
Journal:  J Clin Diagn Res       Date:  2013-04-01

4.  Characterization of a DHA-1-producing Klebsiella pneumoniae strain involved in an outbreak and role of the AmpR regulator in virulence.

Authors:  Claire Hennequin; Frédéric Robin; Nadège Cabrolier; Richard Bonnet; Christiane Forestier
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

Review 5.  Correlation between antimicrobial resistance and virulence in Klebsiella pneumoniae.

Authors:  C Hennequin; F Robin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-30       Impact factor: 3.267

6.  Manno(rhamno)biose-containing capsular polysaccharides of Klebsiella pneumoniae enhance opsono-stimulation of human polymorphonuclear leukocytes.

Authors:  Hany Sahly; Yona Keisari; Itzhak Ofek
Journal:  J Innate Immun       Date:  2008-09-09       Impact factor: 7.349

7.  Loss of hypermucoviscosity and increased fitness cost in colistin-resistant Klebsiella pneumoniae sequence type 23 strains.

Authors:  Myung-Jin Choi; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

8.  Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae.

Authors:  H Sahly; S Navon-Venezia; L Roesler; A Hay; Y Carmeli; R Podschun; C Hennequin; C Forestier; I Ofek
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

9.  Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes.

Authors:  A Abbo; Y Carmeli; S Navon-Venezia; Y Siegman-Igra; M J Schwaber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

10.  Hypervirulent Klebsiella pneumoniae as a hospital-acquired pathogen in the intensive care unit in Mansoura, Egypt.

Authors:  Rasha El-Mahdy; Ghada El-Kannishy; Hassan Salama
Journal:  Germs       Date:  2018-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.